Shopping Cart
- Remove All
Your shopping cart is currently empty
T-1095
Catalog No. T9590Cas No. 209746-59-8
T-1095 is an inhibitor of renal glucose reabsorption and the expression of Na+-glucose cotransporters (SGLTs) and facilitative glucose transporter 2 (GLUT2).
T-1095
Catalog No. T9590Cas No. 209746-59-8
T-1095 is an inhibitor of renal glucose reabsorption and the expression of Na+-glucose cotransporters (SGLTs) and facilitative glucose transporter 2 (GLUT2).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $48 | In Stock | |
| 2 mg | $68 | In Stock | |
| 5 mg | $97 | In Stock | |
| 10 mg | $139 | In Stock | |
| 25 mg | $229 | In Stock | |
| 50 mg | $412 | In Stock | |
| 100 mg | $589 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $136 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "T-1095"
Empagliflozin
Cited
BI 10773
T1766864070-44-0
Empagliflozin (BI 10773) is an SGLT-2 inhibitor (IC50=3.1 nM) that is potent and selective, with more than 300-fold selectivity for SGLT-1/4/5/6. Empagliflozin is used for the treatment of type 2 diabetes.
- $39
Size
QTY
CitedPhlorizin Cited
Phloridzin, NSC 2833, Floridzin
T292260-81-1
Phlorizin (Phloridzin) is a non-selective SGLT inhibitor found in apple, for hSGLT1( Ki=300 nM) and hSGLT2( Ki=39 nM) .
- $46
Size
QTY
CitedDapagliflozin ((2S)-1,2-propanediol, hydrate)
Dapagliflozin propanediol monohydrate, BMS-512148 (2S)-1,2-propanediol, hydrate
T4460960404-48-2
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2), in development for treating type 2 diabetes mellitus (T2DM). It inhibits SGLT2, responsible for at least 90% of glucose reabsorption in the kidney.
- $37
Size
QTY
LDN-212320 Cited
OSU-0212320, LDN-0212320, LDN/OSU-0212320
T15728894002-50-7
LDN-212320 (OSU-0212320) is a glutamate transporter EAAT2 activator. It also enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h.
- $39
Size
QTY
CitedSLC26A3-IN-1
T72054307552-53-0In house
SLC26A3-IN-1 is an inhibitor of the anion-exchange protein SLC26A3 with an IC50 value of 340 nM. SLC26A3, a solute carrier (SLC) protein and member of the SLC26 family, exhibits a wide range of anionic specificities for chloride, bicarbonate, sulfate, and oxalate. Downregulated in adenomas (DRA), SLC26A3 is involved in intestinal absorption of chloride and oxalate and is associated with chloride-losing diarrhea.
- $195
Size
QTY
Dapagliflozin Cited
BMS-512148
T2389461432-26-8
Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.
- $42
Size
QTY
CitedBAY-876 Cited
T37131799753-84-6In house
BAY-876 is an orally active, selective inhibitor of glucose transporter 1 (GLUT1, IC50= 2 nM), exhibiting over 130-fold greater selectivity for GLUT1 than GLUT2, GLUT3, and GLUT4. It also inhibits glycolytic metabolism and ovarian cancer growth.
- $56
Size
QTY
CitedErtugliflozin
PF-04971729, MK-8835
T49991210344-57-2
PF-04971729 (Ertugliflozin (PF-04971729)) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2).
- $45
Size
QTY
Ipragliflozin
ASP1941
T2385761423-87-4
Ipragliflozin (ASP1941) is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.
- $52
Size
QTY
MSNBA
T77657852702-51-3
MSNBA is a selective and potent inhibitor of fructose transport through GLUT5 and also acts as a probe of the GLUT5 transporter. MSNBA inhibited GLUT5 fructose uptake in MCF7 cells with KI of 3.2±0.4 μM.
- $30
Size
QTY
Ertugliflozin L-pyroglutamic acid
PF-04971729 L-pyroglutamic acid
T152441210344-83-4
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM, suitable for studies on the treatment of type 2 diabetes mellitus.
- $39
Size
QTY
Canagliflozin Cited
TA 7284, JNJ 28431754AAA, JNJ 28431754, JNJ 24831754ZAE
T1782842133-18-0
Canagliflozin (JNJ 28431754AAA) is a selective SGLT2 inhibitor that inhibits CHO cells expressing mSGLT2, rSGLT2, and hSGLT2 (IC50=2/3.7/4.4 nM). Canagliflozin can be used for the treatment of type II diabetes mellitus (T2DM).
- $43
Size
QTY
CitedSelect Batch
Purity:99.56%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | T-1095 is an inhibitor of renal glucose reabsorption and the expression of Na+-glucose cotransporters (SGLTs) and facilitative glucose transporter 2 (GLUT2). |
| Targets&IC50 | SGLT2 (human):2.3 μM (IC50), SGLT1 (human):22.8 μM (IC50) |
| In vivo | Administration of 0.03% and 0.1% (wt/wt diet) T-1095 to STZ rats for 4 weeks improved the hyperglycemia and dose-dependently decreased HbA1c[1]. Moreover, treatment with 0.1% (wt/wt diet) T-1095 in STZ rats for 8 weeks not only reduced blood glucose and HbA1c, levels but also prevented the elevation of urinary albumin levels and kidney weight and the development of epithelial vacuolation[1]. The expression of renal SGLT2, a major glucose transporter in the kidney, was not different in normal, STZ, and T-1095-treated STZ rats. In contrast, the elevated renal GLUT2 level in STZ rats was suppressed by T-1095[1]. |
| Molecular Weight | 516.49 |
| Formula | C26H28O11 |
| Cas No. | 209746-59-8 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (116.17 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy T-1095 | purchase T-1095 | T-1095 cost | order T-1095 | T-1095 chemical structure | T-1095 in vivo | T-1095 formula | T-1095 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.